US FDA Approves Diabetes Drug by Provention Bio
The US Food and Drug Administration (FDA) has approved the use of Provention Bio’s drug teplizumab in those aged eight years and older, said Povention Bio. According to Provention Bio, the first treatment aimed at delaying the onset of type-1 diabetes dependent on insulin. The US FDA has allowed teplizumab, to be sold under the […]
Continue Reading